Thyrocare TechnologiesQ4 FY24

Thyrocare Technologies Q4 FY24 Earnings Call Analysis

Revenue, margin, capex, fundraise and order book outlook from management commentary.

Price: ₹506.95P/E: 46.1Market Cap: ₹8.1K CrSector: Healthcare Services

Management growth scorecard

Revenue

Category 3

Margin

Category 3

Fundraise

N/A

Order

N/A

Capex

Yes

1 of 3 growth signals are positive — mixed outlook.

Full analysis

Revenue guidance

Category 3
  • FY25 growth guidance targets mid-teen revenue growth of 15%-18% (Alok Jagnani).
  • Franchisee business expected to return to high teens growth rate post stabilization of small franchisee churn.
  • Partnership business excluding API and B2G expected to continue strong growth, leveraging hospital and insurance segment expansions.
  • Volume growth: Core franchise business grew 8% in FY24 (year-on-year) with 10% quarter-on-quarter sample growth.
  • Focus on geographic expansion deeper into India, enhanced service offerings (e.g., ECG at home via Think Health acquisition).
  • Marketing investments continue to promote new packages like JAANCH and Her Check driving brand growth.
  • New international market entry: Tanzania launch anticipated to open significant affordable testing opportunities.
  • Expect revenue growth driven by a mix shift towards larger franchisees and strategic partnerships, not just price increases.
  • Promotion costs and new initiatives investment to sustain growth momentum.

See what Thyrocare Technologies management said on margin guidance — free account, 30 seconds.

Fundraise plans

  • There is no explicit mention of any current or future fundraising through debt or equity in the provided transcript.
  • A question was raised about promoters' pledged shares and recent fundraise, but no specific details on new fundraising plans were disclosed.
  • The company discussed ongoing investments in marketing, new business expansions (e.g., Tanzania, Think Health), but funding sources were not detailed.
  • ESOPs are in place as a talent retention mechanism, recorded as expenses but not cash outflows.
  • Overall, the management focused on organic growth and strategic investments without indicating plans for fresh debt or equity issuance.

See what Thyrocare Technologies management said on order book — free account, 30 seconds.

Capex plans

Yes
  • Thyrocare is investing in geographic expansion, including a new venture in Tanzania, aiming to launch affordable diagnostic tests in that country.
  • The company is scaling up Think Health, which provides ECG at home services, enhancing offerings especially for insurance partners.
  • They continue investing in quality improvements, expanding reach, and improving turnaround time to maintain best-in-class service.
  • Marketing and promotion costs of approximately Rs. 8-10 crores were spent in FY24, mainly to promote new packages and brand JAANCH.
  • Investments are also being made in partnerships with hospitals and insurance sectors to drive growth.
  • Capex in new initiatives like Tanzania and Think Health may initially impact margins but are expected to deliver long-term operating leverage.
  • No specific detailed capital expenditure amounts disclosed beyond marketing spends and startup costs for new initiatives.

Track Thyrocare Technologies — get its next earnings analysis in your feed

How does Thyrocare Technologies rank vs peers in Healthcare Services?

Pro feature
ThisThyrocare Technologies
Rev 3Mar 3

How does Thyrocare Technologies rank in Healthcare Services?

Compare Thyrocare Technologies against every Healthcare Services company (Q4 FY24) on revenue, margins and earnings-call signals.

View Healthcare Services leaderboard →

Others in Healthcare Services this season

  • Chandan Healthca (Q2 FY27)

    Q2 FY27 operating income: ₹57.94 Cr, up 45.04% YoY from ₹39.95 Cr (Page 8) . Key investor presentation takeaways from Chandan Healthcare Ltd's Q2 FY27 investor

  • Invicta Diagnostic (Q2 FY27)

    Revenue from operations for the half year ended September 30, 2026: ₹379.11 lakhs (Page 4). Key results statement takeaways from Invicta Diagnostic Ltd's Q2 FY2

  • Unihealth Hosp (Q2 FY27)

    1,270 million with a year-on-year (YoY) growth of 6.3% . Key results statement takeaways from Unihealth Hospitals Ltd's Q2 FY27 results statement — and how it r

  • Sangani Hospital (Q2 FY27)

    1008.56 lakhs (~11.8% increase). Key results statement takeaways from Sangani Hospitals Ltd's Q2 FY27 results statement — and how it ranks against sector peers.

🔎 Who's planning the most growth?

Companies ranked by management's own guidance — revenue, margins, capex and order book, from every earnings call in India.

See rankings →